To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with
cABSSSI (major cutaneous abscesses) due to MRSA.
- To assess the pharmacokinetics of CG400549 (960 mg daily) in subjects with cABSSSI due
- To explore the in vitro susceptibility of cABSSSI-related bacteria to CG400549.
- To assess the safety of multiple doses of CG400459